Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Tingyu Yu, Jianxiang Chi & Li Wang. (2021) Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. Hematology 26:1, pages 848-859.
Read now
Read now
Ya-Zhen Qin, Lan-Ping Xu, Huan Chen, Qian Jiang, Yu Wang, Hao Jiang, Xiao-Hui Zhang, Wei Han, Yu-Hong Chen, Feng-Rong Wang, Jing-Zhi Wang, Hong-Hu Zhu, Yan-Rong Liu, Bin Jiang, Kai-Yan Liu & Xiao-Jun Huang. (2015) Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. Leukemia & Lymphoma 56:11, pages 3116-3123.
Read now
Read now
Nicolas Duployez, Christophe Willekens, Alice Marceau-Renaut, Elise Boudry-Labis & Claude Preudhomme. (2015) Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Review of Hematology 8:1, pages 43-56.
Read now
Read now
Jana Marková, Jana Marková, Zuzana Trnková, Petra Michková, Jacqueline Maaloufová, Jan Starý, Petr Cetkovský & Jiří Schwarz. (2009) Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leukemia & Lymphoma 50:9, pages 1448-1460.
Read now
Read now
Articles from other publishers (39)
Michael Krigstein, Harry J. Iland & Andrew H. Wei. (2023) Applying molecular measurable residual disease testing in acute myeloid leukaemia. Pathology 55:1, pages 1-7.
Crossref
Crossref
Lei Shang, Xiaojin Cai, Wanchen Sun, Qingnian Cheng & Yingchang Mi. (2021)
Time point‐dependent concordance and prognostic significance of flow cytometry and real time quantitative
PCR
for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1)
. Cytometry Part B: Clinical Cytometry 102:1, pages 34-43.
Crossref
Crossref
Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel & Nicholas J. Short. (2021) Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Anne‐Sofie Skou, Kristian Løvvik Juul‐Dam, Hans B. Ommen & Henrik Hasle. (2021) Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse. British Journal of Haematology 195:3, pages 310-327.
Crossref
Crossref
Annalisa Talami, Francesca Bettelli, Valeria Pioli, Davide Giusti, Andrea Gilioli, Corrado Colasante, Laura Galassi, Rachele Giubbolini, Hillary Catellani, Francesca Donatelli, Rossana Maffei, Silvia Martinelli, Patrizia Barozzi, Leonardo Potenza, Roberto Marasca, Tommaso Trenti, Enrico Tagliafico, Patrizia Comoli, Mario Luppi & Fabio Forghieri. (2021) How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. Biomedicines 9:8, pages 953.
Crossref
Crossref
Guang Yang & Linsheng Zhang. 2021. Practical Oncologic Molecular Pathology. Practical Oncologic Molecular Pathology
275
304
.
Jan Philipp Bewersdorf, Rory M. Shallis, Prajwal C. Boddu, Brent Wood, Jerald Radich, Stephanie Halene & Amer M. Zeidan. (2020) The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia. Blood Reviews 43, pages 100650.
Crossref
Crossref
Robert Puckrin, Eshetu G. Atenafu, Jaime O. Claudio, Steven Chan, Vikas Gupta, Dawn Maze, Caroline McNamara, Tracy Murphy, Andre C. Shuh, Karen Yee, Hassan Sibai, Mark D. Minden, Cuihong Wei, Tracy Stockley, Suzanne Kamel-Reid & Aaron D. Schimmer. (2020) Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica 106:1, pages 56-63.
Crossref
Crossref
Mats Ehinger & Louise Pettersson. (2019) Measurable residual disease testing for personalized treatment of acute myeloid leukemia. APMIS 127:5, pages 337-351.
Crossref
Crossref
Ine Moors, Karl Vandepoele, Jan Philippé, Dries Deeren, Dominik Selleslag, Dimitri Breems, Nicole Straetmans, Tessa Kerre & Barbara Denys. (2019) Clinical implications of measurable residual disease in AML: Review of current evidence. Critical Reviews in Oncology/Hematology 133, pages 142-148.
Crossref
Crossref
Zhuang Liu, Wenjun Wang, Chaofeng Zheng, Yanhong Tan, Xiuhua Chen, Jing Xu, Zhifang Xu, Fanggang Ren, Yaofang Zhang, Guoxia Li, Jianmei Chang & Hongwei Wang. (2018) Clinical significance of droplet digital PCR quantitative monitoring of KIT gene mutation levels in core binding factor leukemia. International Journal of Laboratory Hematology 40:6, pages e124-e126.
Crossref
Crossref
Prajwal Boddu, Christopher Gurguis, David Sanford, Jorge Cortes, Mary Akosile, Farhad Ravandi, Guillermo Garcia-Manero, Keyur P Patel, Tapan Kadia, Mark Brandt, Rita Maduike, Hagop Kantarjian & Gautam Borthakur. (2018) Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia 32:12, pages 2698-2701.
Crossref
Crossref
Elaine Coustan-Smith, Guangchun Song, Sheila Shurtleff, Allen Eng-Juh Yeoh, Wee Joo Chng, Siew Peng Chen, Jeffrey E. Rubnitz, Ching-Hon Pui, James R. Downing & Dario Campana. (2018) Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight 3:9.
Crossref
Crossref
Ya-Zhen Qin, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Wei Han, Yu-Hong Chen, Feng-Rong Wang, Jing-Zhi Wang, Yao Chen, Xiao-Dong Mo, Xiao-Su Zhao, Ying-Jun Chang, Kai-Yan Liu & Xiao-Jun Huang. (2017) The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Barbara J. Bain. 2017. Leukaemia Diagnosis. Leukaemia Diagnosis
135
248
.
Cordelia Sever, Charles L. Abbott, Monica E. de Baca, Joseph D. Khoury, Sherrie L. Perkins, Kaaren Kemp Reichard, Ann Taylor, Howard R. Terebelo, Carol Colasacco, R. Bryan Rumble & Nicole E. Thomas. (2016) Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center. Archives of Pathology & Laboratory Medicine 140:9, pages 932-949.
Crossref
Crossref
L.L. Girshova, Ekaterina Gennad'evna Ovsyannikova, S.O. Kuzin, E.N. Goryunova, R.I. Vabishchevich, A.V. Petrov, D.V. Motorin, D.V. Babenetskaya, V.V. Ivanov, K.V. Bogdanov, I.V. Kholopova, T.S. Nikulina, Yu.V. Mirolyubova, Yu.A. Alekseeva & A.Yu. Zaritskii. (2016) Molecular Monitoring of RUNX1-RUNX1T1 Transcript Level in Acute Myeloblastic Leukemias on Treatment. Clinical oncohematology 9:4, pages 456-464.
Crossref
Crossref
. 2016. Diagnostic Pathology: Molecular Oncology. Diagnostic Pathology: Molecular Oncology
5-96
5-101
.
Ehsan Ghayoor Karimiani & Abolghasem Allahyari. (2015) Role of Stem Cell Elements in Chronic Myeloid Leukemia. Razavi International Journal of Medicine 3:1.
Crossref
Crossref
Melhem Solh, Sophia Yohe, Daniel Weisdorf & Celalettin Ustun. (2014) Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. American Journal of Hematology 89:12, pages 1121-1131.
Crossref
Crossref
Li Zhang, Zeng Cao, Min Ruan, Qiang Zeng, Liang Zhao, Qinghua Li, Yao Zou, Jianxiang Wang & Xiaofan Zhu. (2014) Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia. Pediatric Blood & Cancer 61:10, pages 1761-1766.
Crossref
Crossref
Yu WangDe-Pei WuQi-Fa LiuYa-Zhen QinJing-Bo Wang, Lan-Ping XuYan-Rong LiuHong-Hu ZhuJia ChenMin DaiXiao-Jun Huang. (2014) In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood 124:12, pages 1880-1886.
Crossref
Crossref
Dario Campana & Ching-Hon Pui. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1849
1872.e11
.
LI-SHENG LIN, LI-NA LIU, HUI-FANG HUANG, YUAN-ZHONG CHEN, BU-HONG LI & ZHENG HUANG. (2013) CHARACTERIZING FLUORESCENCE LIFETIME OF NAD(P)H IN HUMAN LEUKEMIC MYELOID CELLS AND MONONUCLEAR CELLS. Journal of Innovative Optical Health Sciences 06:04, pages 1350042.
Crossref
Crossref
Jae-Ho Yoon, Hee-Je Kim, Seung-Hwan Shin, Seung-Ah Yahng, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park & Ji-Hyang Lim. (2013)
BAALC
and
WT1
expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML
. European Journal of Haematology 91:2, pages 112-121.
Crossref
Crossref
Lixia Zhang, Qinghua Li, Wei Li, Bingcheng Liu, Ying Wang, Dong Lin, Chunlin Zhou, Chengwen Li, Jianxiang Wang & Yingchang Mi. (2013) Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22). International Journal of Hematology 97:6, pages 786-792.
Crossref
Crossref
Hong-Hu ZhuXiao-Hui ZhangYa-Zhen QinDai-Hong LiuHao JiangHuan ChenQian JiangLan-Ping XuJin LuWei HanLi BaoYu WangYu-Hong ChenJing-Zhi WangFeng-Rong WangYue-Yun LaiJun-Yue ChaiLi-Ru Wang, Yan-Rong LiuKai-Yan LiuBin JiangXiao-Jun Huang. (2013) MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 121:20, pages 4056-4062.
Crossref
Crossref
Elaine Coustan-Smith & Dario Campana. (2013) Should evaluation for minimal residual disease be routine in acute myeloid leukemia?. Current Opinion in Hematology 20:2, pages 86-92.
Crossref
Crossref
Hiroto InabaElaine Coustan-SmithXueyuan CaoStanley B. PoundsSheila A. ShurtleffKathleen Y. WangSusana C. RaimondiMihaela OnciuJeffrey JacobsenRaul C. RibeiroGary V. DahlW. Paul BowmanJeffrey W. TaubBarbara DegarWing LeungJames R. DowningChing-Hon PuiJeffrey E. RubnitzDario Campana. (2012) Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. Journal of Clinical Oncology 30:29, pages 3625-3632.
Crossref
Crossref
Klaus Geissler & Otto Zach. (2012) Pathways involved in Drosophila and human cancer development: the Notch, Hedgehog, Wingless, Runt, and Trithorax pathway. Annals of Hematology 91:5, pages 645-669.
Crossref
Crossref
Dario CampanaElaine Coustan-Smith. (2012) Measurements of treatment response in childhood acute leukemia. The Korean Journal of Hematology 47:4, pages 245.
Crossref
Crossref
Steven W. Lane & David A. Williams. 2012. Advances in Cancer Stem Cell Biology. Advances in Cancer Stem Cell Biology
85
103
.
M. Sato, J. Yamazaki, Y. Goto‐Koshino, M. Takahashi, Y. Fujino, K. Ohno & H. Tsujimoto. (2011) Increase in Minimal Residual Disease in Peripheral Blood before Clinical Relapse in Dogs with Lymphoma that Achieved Complete Remission after Chemotherapy. Journal of Veterinary Internal Medicine 25:2, pages 292-296.
Crossref
Crossref
Karen P. Mann & Debra F. Saxe. 2011. Hematopathology. Hematopathology
127
155
.
Barbara J. Bain. 2010. Leukaemia Diagnosis. Leukaemia Diagnosis
114
218
.
Marie E. Beckner & Jeffrey A. Kant. 2010. Molecular Pathology of Hematolymphoid Diseases. Molecular Pathology of Hematolymphoid Diseases
153
164
.
Gautam Borthakur, E Lin, Nitin Jain, Elihu E. Estey, Jorge E. Cortes, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Sherry Pierce & Hagop Kantarjian. (2009) Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia. Cancer 115:14, pages 3217-3221.
Crossref
Crossref
H Tamaki, S Yoshihara, T Fujioka, M Kawakami, Y Oka & H Ogawa. (2008) Molecular detection of AML1-MTG8-positive cells in peripheral blood from a patient with isolated extramedullary relapse of t(8;21) acute myeloid leukemia. Leukemia 23:2, pages 424-426.
Crossref
Crossref
Krzysztof Mrózek, Guido Marcucci, Peter Paschka & Clara D Bloomfield. (2008) Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Current Opinion in Oncology 20:6, pages 711-718.
Crossref
Crossref